1. Scrip
  2. >>Business
  3. >>Strategy

EASDAQ: Fighting for a Lost Cause?

 
• By Melanie Senior

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks--but it hasn't won the war either. Despite its aim of providing growth companies with European-wide exposure, using a single regulatory environment and trading system--the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

Five years after its formation, Easdaq still hasn't given up the fight to become the pan-European market for growth stocks—but it hasn't won the war, either. Despite its laudable aim—to provide growth companies with European-wide exposure, using a single regulatory environment and trading system—the Brussels-based exchange has so far failed to become the Nasdaq of Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.